Clinical Predictors of Response to Tocilizumab: A Retrospective Multicenter Study.

Ercan S., Ergan B., Özuygur S. S., Korkmaz P., Taşbakan M. S., Basoglu Ö. K., ...Daha Fazla

Turkish thoracic journal, cilt.23, sa.3, ss.225-230, 2022 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 23 Sayı: 3
  • Basım Tarihi: 2022
  • Doi Numarası: 10.5152/turkthoracj.2022.21179
  • Dergi Adı: Turkish thoracic journal
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.225-230
  • Anahtar Kelimeler: Tocilizumab, COVID-19, mortality, biomarkers, CALL score
  • Atatürk Üniversitesi Adresli: Evet

Özet

OBJECTIVE: A substantial number of patients with coronavirus disease-2019 (COVID-19) demonstrate severe infection. Cytokine storm is an underlying condition that worsens clinical outcomes. As an interleukin-6 receptor antagonist, tocilizumab is a promising treatment option for COVID-19. This study aimed to evaluate the clinical predictors of mortality for critically ill COVID-19 patients receiving tocilizumab therapy.